Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/Unfit Double-Expressor DLBCL
NCT07884708Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 3 years. Started Mar 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07884708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884708.